159 related articles for article (PubMed ID: 38377684)
1. Use of perioperative telotristat in a patient with carcinoid heart disease.
Flynn M; Noss C; Miller R; Adams C; Ruether D; Chan D; Pasieka J; Lithgow K
Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38377684
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
3. Balancing carcinoid crisis and right ventricular dysfunction during tricuspid and pulmonic valve replacement for carcinoid heart disease: A case report.
Pagryzinski AR; Schena S; Novalija J; Almassi GH; Pagel PS; Hang D
Int J Surg Case Rep; 2023 Jan; 102():107855. PubMed ID: 36610355
[TBL] [Abstract][Full Text] [Related]
4. Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?
Herrera-Martínez AD; Fuentes-Fayos AC; Sanchez-Sanchez R; Montero AJ; Sarmento-Cabral A; Gálvez-Moreno MA; Gahete MD; Luque RM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396713
[TBL] [Abstract][Full Text] [Related]
5. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.
Masab M; Saif MW
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1055-1062. PubMed ID: 29051994
[TBL] [Abstract][Full Text] [Related]
6. Telotristat ethyl: a new option for the management of carcinoid syndrome.
Lamarca A; Barriuso J; McNamara MG; Hubner RA; Valle JW
Expert Opin Pharmacother; 2016 Dec; 17(18):2487-2498. PubMed ID: 27817224
[TBL] [Abstract][Full Text] [Related]
7. Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities.
Lenneman C; Harrison D; Davis SL; Kondapalli L
Curr Treat Options Oncol; 2022 Dec; 23(12):1793-1803. PubMed ID: 36417147
[TBL] [Abstract][Full Text] [Related]
8. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
9. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
10. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Kulke MH; Hörsch D; Caplin ME; Anthony LB; Bergsland E; Öberg K; Welin S; Warner RR; Lombard-Bohas C; Kunz PL; Grande E; Valle JW; Fleming D; Lapuerta P; Banks P; Jackson S; Zambrowicz B; Sands AT; Pavel M
J Clin Oncol; 2017 Jan; 35(1):14-23. PubMed ID: 27918724
[TBL] [Abstract][Full Text] [Related]
11. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
12. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust K; Maschio M; Kohli M; Singh S; Pritchard DM; Marteau F; Myrenfors P; Feuilly M
Pharmacoeconomics; 2020 Jun; 38(6):607-618. PubMed ID: 32157590
[TBL] [Abstract][Full Text] [Related]
13. Tricuspid valve regurgitation as a presenting symptom of metastasized carcinoid tumor.
Engelsman AF; van Duijvendijk P; Groenemeijer BE; van der Zaag E; Spronk PE; Katinakis A
Case Rep Gastroenterol; 2012 Sep; 6(3):643-9. PubMed ID: 23139656
[TBL] [Abstract][Full Text] [Related]
14. [Surgical treatment of carcinoid heart disease].
Watanabe T; Ohshima N; Shirai T; Someya T
Kyobu Geka; 2010 Oct; 63(11):999-1003. PubMed ID: 20954358
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of left-sided carcinoid heart disease.
Connolly HM; Schaff HV; Mullany CJ; Rubin J; Abel MD; Pellikka PA
Circulation; 2001 Sep; 104(12 Suppl 1):I36-40. PubMed ID: 11568027
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
17. Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Bober B; Saracyn M; Kołodziej M; Kowalski Ł; Deptuła-Krawczyk E; Kapusta W; Kamiński G; Mozenska O; Bil J
Clin Med Insights Cardiol; 2020; 14():1179546820968101. PubMed ID: 33192110
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in diagnosis and perioperative management of carcinoid heart disease.
Castillo JG; Silvay G; Solís J
Semin Cardiothorac Vasc Anesth; 2013 Sep; 17(3):212-23. PubMed ID: 23171718
[TBL] [Abstract][Full Text] [Related]
19. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
20. Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.
Kasi PM
Drugs Today (Barc); 2018 Jul; 54(7):423-432. PubMed ID: 30090879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
